title: Male sexual function after autologous blood or marrow transplantation.
abstract: Although endocrine dysfunction has been reported in survivors of allogeneic bone marrow transplantation (alloBMT), data for autologous BMT (autoBMT) recipients are lacking. Because information on male potency in particular is scanty, we prospectively assessed male sexual function after autoBMT. We identified 16 men who were < or =50 years of age at the time of evaluation and disease free for at least 6 months after autoBMT. Nine had Hodgkin's disease, 4 had acute myelogenous leukemia, and 3 had non-Hodgkin's lymphoma. Blood samples were assayed for luteinizing hormone (LH), follicle-stimulating hormone (FSH), and testosterone. Patients were surveyed with a modified version of the Pyschosocial Adjustment to Illness Scale regarding erectile dysfunction and loss of interest in sexual activities. Seventy five percent of the men reported normal interest in sexual activities and 87.5% reported normal erectile function; however, 4 of 16 reported a moderate loss of interest in sexual activities, and another 2 of 16 reported frequent loss of erectile function. All 4 men with decreased libido and both men with impaired erectile function had Hodgkin's disease. Fourteen (88%) of 16 patients had an elevated FSH level, 7 (47%) of 15 had elevated LH, and 6 (38%) of 16 had decreased testosterone levels. Decreased testosterone levels correlated with a moderate or total loss of libido (P = .008) and a diagnosis of Hodgkin's disease (P = .01). Thus, after transplantation, most men have abnormal levels of gonadotrophins. Decreased levels of testosterone and symptoms of sexual dysfunction correlated with a diagnosis of Hodgkin's disease and may be related to the induction and salvage therapy received prior to autoBMT.
authors.affiliation: Autologous Blood and Marrow Transplant Long-Term Follow-up Research Unit, The Princess Margaret Hospital, University Health Network, Toronto, Ontario, Canada. aaron.schimmer@utoronto.ca
authors.forename: A D
authors.initials: AD
authors.lastname: Schimmer
authors.forename: V
authors.initials: V
authors.lastname: Ali
authors.forename: A K
authors.initials: AK
authors.lastname: Stewart
authors.forename: K
authors.initials: K
authors.lastname: Imrie
authors.forename: A
authors.initials: A
authors.lastname: Keating
mesh_terms: D000328:Adult; D016026:Bone Marrow Transplantation / Q000009:adverse effects; D003625:Data Collection; D007172:Erectile Dysfunction / Q000097:blood / Q000209:etiology*; D005640:Follicle Stimulating Hormone / Q000097:blood; D005500:Follow-Up Studies; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D013739:Testosterone / Q000097:blood; D013997:Time Factors; D014182:Transplantation, Autologous / Q000009:adverse effects*
chemical_list: D013739:Testosterone; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone